BRCA1 and familial pancreatic carcinoma: Identification of BRCA1 and BRCA2 mutations offers potential therapeutic advantages as they confer increased sensitivity to PARPi, reflecting a unique biology of BRCA-mutated pancreatic cancer cells [36,37].